mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Although FOLFIRINOX regimen was recently presented to be effective as adjuvant chemotherapy
for resectable pancreatic cancer in selected patients who have good physical condition, there
is still insufficient evidence on this regimen in treating resectable pancreatic cancer
patients in China. Since for many tumors, different races may show different responses to the
same regimen, we design this open phase Ⅱ study to evaluate the the efficacy and safety of
mFOLFIRINOX as adjuvant chemotherapy for resectable pancreatic cancer in China.